D.A. Davidson & CO. grew its holdings in shares of Fresenius Medical Care Corporation (NYSE:FMS) by 6.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 16,854 shares of the company’s stock after purchasing an additional 1,077 shares during the period. D.A. Davidson & CO.’s holdings in Fresenius Medical Care were worth $823,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in shares of Fresenius Medical Care by 37.6% during the third quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock valued at $250,000 after acquiring an additional 1,394 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Fresenius Medical Care in the 3rd quarter worth approximately $527,000. Fragasso Group Inc. grew its position in Fresenius Medical Care by 11.4% in the 3rd quarter. Fragasso Group Inc. now owns 23,139 shares of the company’s stock worth $1,131,000 after purchasing an additional 2,375 shares during the period. Comerica Bank grew its position in Fresenius Medical Care by 4.1% in the 3rd quarter. Comerica Bank now owns 47,848 shares of the company’s stock worth $2,317,000 after purchasing an additional 1,876 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Fresenius Medical Care by 4.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,263 shares of the company’s stock worth $2,604,000 after purchasing an additional 2,429 shares during the period. Hedge funds and other institutional investors own 2.78% of the company’s stock.

A number of research analysts recently weighed in on the stock. BidaskClub cut shares of Fresenius Medical Care from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Royal Bank Of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care in a research note on Tuesday, August 1st. DZ Bank AG reiterated a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, August 7th. Finally, Zacks Investment Research cut shares of Fresenius Medical Care from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Fresenius Medical Care presently has an average rating of “Hold” and an average target price of $48.50.

Shares of Fresenius Medical Care Corporation (NYSE:FMS) opened at $49.36 on Monday. Fresenius Medical Care Corporation has a 52-week low of $38.20 and a 52-week high of $50.22. The firm has a market cap of $30,392.04, a P/E ratio of 22.13, a PEG ratio of 2.23 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98.

WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/27/d-a-davidson-co-has-823000-stake-in-fresenius-medical-care-corporation-fms.html.

About Fresenius Medical Care

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Institutional Ownership by Quarter for Fresenius Medical Care (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.